Short answer
Disc Medicine, Inc. (IRON) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results cover the quarter ended September 30, 2026.
Disc Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results cover the quarter ended September 30, 2026
- Corporate update announced alongside the quarterly financial results
- Detailed financial figures and business developments available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- APOLLO Phase 3 met all primary and secondary endpoints, materially strengthening bitopertin’s path toward EPP approval
- Bitopertin reduced PPIX 41.4% versus placebo and increased monthly pain-free sunlight exposure by 12.2 hours
- NDA resubmission planned by end-2026, with potential FDA decision anticipated by mid-2027
- Cash $682.8M at Q3-end, plus $485.9M October offering proceeds, extending expected funding runway into 2030
- Q3 net loss $59.5M, with R&D $44.1M and SG&A $20.1M; pipeline spending remains substantial despite lower quarterly loss
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Disc Medicine, Inc. 8-K filings
Get the next IRON 8-K as it lands
Follow IRON for push alerts, or ask the research agent what this filing means.